IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

Genes and Immunity

Volumn 12, Issue 4, 2011, Pages 300-309

  Chen, J Y ^a   Lin, C Y ^a   Wang, C M ^a   Lin, Y T ^a   Kuo, S N ^a   Shiu, C F ^b   Chang, S W ^b   Wu, J ^c   Sheen, I S ^a  

^a CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c UNIVERSITY OF MINNESOTA   (United States)

Author keywords

hepatitis C; IL28B; single nucleotide polymorphisms; sustained virological response

Indexed keywords

INTERLEUKIN 28; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALLELE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; ASIAN; CONTROLLED STUDY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HAPLOTYPE; HEPATITIS C; HUMAN; HUMAN TISSUE; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; AGED; ALLELES; DRUG THERAPY, COMBINATION; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; RIBAVIRIN; TAIWAN; YOUNG ADULT;

HEPATITIS C VIRUS;

EID: 79957982710     PISSN: 14664879     EISSN: 14765470     Source Type: Journal    
DOI: 10.1038/gene.2011.1     Document Type: Article

References (60)

1. Shepard CW, Finelli L, Alter M. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5: 558-567. (Pubitemid 41196755)
2. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29: 908-914. (Pubitemid 29109609)
3. Thimme R, Oldach D, Chang KM, Steiger C, Ray SC, Chisari FV. Determinants of viral clearance and persistence during acute hepatitis C virus infection. J Exp Med 2001; 194: 1395-1406. (Pubitemid 33081515)
4. Pachiadakis I, Pollara G, Chain BM, Naoumov NV. Is hepatitis C virus infection of dendritic cells a mechanism facilitating viral persistence? Lancet Infect Dis 2005; 5: 296-304. (Pubitemid 40602249)
5. Bialek SR, Terrault NA. The changing epidemiology and natural history of hepatitis C virus infection. Clin Liver Dis 2006; 10: 697-715. (Pubitemid 44880154)
6. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet 1997; 349: 825-832. (Pubitemid 27129209)
7. Blonski W, Reddy KR. Hepatitis C virus infection and hepatocellular carcinoma. Clin Liver Dis 2008; 12: 661-674. (Pubitemid 351952471)
8. Kawai T, Akira S. Innate immune recognition of viral infection. Nat Immunol 2006; 7: 131-137. (Pubitemid 43135878)
9. Cheng G, Zhong J, Chung J, Chisari FV. Double-stranded DNA and double-stranded RNA induce a common antiviral signaling pathway in human cells. Proc Natl Acad Sci USA 2007; 104: 9035-9040. (Pubitemid 47175432)
10. Szabo G, Dolganiuc A, Mandrekar P. Pattern recognition receptors: a contemporary view on liver diseases. Hepatology 2006; 44: 287-298. (Pubitemid 44214866)
11. Saito T, Owen DM, Jiang F, Marcotrigiano J, Gale Jr M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus RNA. Nature 2008; 454: 523-527.
12. Kanto T, Hayashi N. Innate immunity in hepatitis C virus infection: Interplay among dendritic cells, natural killer cells and natural killer T cells. Hepatol Res 2007; 37 (Suppl 3): S319-S326. (Pubitemid 47570639)
13. National Institute of Health U.S.A. NIH consensus statement on management of hepatitis C. NIH Consens State Sci Statements 2002; 19: 1-46.
14. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA 2000; 284: 450-456. (Pubitemid 30484478)
15. Lechner F, Wong DKH, Dunbar PR, Chapman R, Chung RT, Dohrenwend P et al. Analysis of successful immune responses in persons infected with hepatitis C virus. J Exp Med 2000; 191: 1499-1512. (Pubitemid 30257347)
16. Thimme R, Lohmann V, Weber F. A target on the move: innate and adaptive immune escape strategies of hepatitis C virus. Antiviral Res 2006; 69: 129-141. (Pubitemid 43247333)
17. Missale G, Cariani E, Ferrari C. Role of viral and host factors in HCV persistence: which lesson for therapeutic and preventive strategies? Dig Liver Dis 2004; 36: 703-711. (Pubitemid 41070589)
18. Szabo G, Dolganiuc A. Hepatitis C and innate immunity: recent advances. Clin Liver Dis 2008; 12: 675-692. (Pubitemid 351952475)
19. Rehermann B. Hepatitis C virus versus innate and adaptive immune responses: a tale of coevolution and coexistence. J Clin Invest 2009; 119: 1745-1754.
20. Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, Shah NK et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 2003; 4: 69-77. (Pubitemid 36109115)
21. Li M, Liu X, Zhou Y, Su SB. Interferon-lambdas: the modulators of antivirus, antitumor, and immune responses. J Leukoc Biol 2009; 86: 23-32.
22. Coccia EM, Severa M, Giacomini E, Monneron D, Remoli ME, Julkunen I et al. Viral infection and Toll-like receptor agonists induce a differential expression of type I and lambda interferons in human plasmacytoid and monocyte-derived dendritic cells. Eur J Immunol 2004; 34: 796-805. (Pubitemid 39255927)
23. Ank N, West H, Bartholdy C, Thomsen AR, Paludan SR. Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 2006; 80: 4501-4509.
24. Dellgren C, Gad HH, Hamming OJ, Melchjorsen J, Hartmann R. Human interferon-lambda3 is a potent member of the type III interferon family. Genes Immun 2009; 10: 125-131.
25. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009; 461: 399-401.
26. Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML et al. IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 2009; 41: 1100-1104.
27. Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N et al. Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 2009; 10: 1105-1109.
28. Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, Mueller T et al. Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure-a genome-wide association study. Gastroenteroloy 2010; 138: 1338-1345.
29. Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, O'Huigin C et al. Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 2009; 461: 798-801.
30. Lloyd AR, Jagger E, Post JJ, Crooks LA, Rawlinson WD, Hahn YS et al. Host and viral factors in the immunopathogenesis of primary hepatitis C virus infection. Immunol Cell Biol 2007; 85: 24-32. (Pubitemid 46067318)
31. Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev Immunol 2005; 5: 215-229. (Pubitemid 40364823)
32. Gale Jr M, Foy EM. Evasion of intracellular host defense by hepatitis C virus. Nature 2005; 436: 939-945. (Pubitemid 41191669)
33. Hiroishi K, Ito T, Imawari M. Immune responses in hepatitis C virus infection and mechanisms of hepatitis C virus persistence. J Gastroenterol Hepatol 2008; 23: 1473-1482.
34. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. J Biol Chem 2009; 284: 20869-20875.
35. Marcello T, Grakoui A, Barba-Spaeth G, Machlin ES, Kotenko SV, MacDonald MR et al. Interferons alpha and lambda inhibit hepatitis C virus replication with distinct signal transduction and gene regulation kinetics. Gastroenter-ology 2006; 131: 1887-1898. (Pubitemid 44958521)
36. Robek MD, Boyd BS, Chisari FV. Lambda interferon inhibits hepatitis B and C virus replication. J Virol 2005; 79: 3851-3854. (Pubitemid 40327973)
37. Zhu H, Butera M, Nelson DR, Liu C. Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication. Virol J 2005; 2: 80.
38. Pagliaccetti NE, Eduardo R, Kleinstein SH, Mu XJ, Bandi P, Robek MD. Interleukin-29 functions cooperatively with inter-feron to induce antiviral gene expression and inhibit hepatitis C virus replication. J Biol Chem 2008; 283: 30079-30089.
39. Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, Jensen UB et al. An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. J Immunol 2008; 180: 2474-2485.
40. Taylor MW, Tsukahara T, Brodsky L, Schaley J, Sanda C, Stephens MJ et al. Changes in gene expression during pegylated interferon and ribavirin therapy of chronic hepatitis C virus distinguish responders from nonresponders to antiviral therapy. J Virol 2007; 81: 3391-3401. (Pubitemid 46456648)
41. Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, Filipowicz W et al. Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci USA 2008; 105: 7034-7039. (Pubitemid 351754525)
42. Feld JJ, Nanda S, Huang Y, Chen W, Cam M, Pusek SN et al. Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology 2007; 46: 1548-1563. (Pubitemid 350155537)
43. Welzel TM, Morgan TR, Bonkovsky HL, Naishadham D, Pfeiffer RM, Wright EC et al. Variants in interferon-alpha pathway genes and response to pegylated interferon-Alpha2a plus ribavirin for treatment of chronic hepatitis C virus infection in the hepatitis C antiviral long-term treatment against cirrhosis trial. HALT-C Trial Group. Hepatology 2009; 49: 1847-1858.
44. Su X, Yee LJ, Im K, Rhodes SL, Tang Y, Tong X et al. Association of single nucleotide polymorphisms in interferon signaling pathway genes and interferon-stimulated genes with the response to interferon therapy for chronic hepatitis C. Virahep-C Study Group. J Hepatol 2008; 49: 184-191.
45. Chen L, Sun J, Meng L, Heathcote J, Edwards AM, McGilvray ID. ISG15, a ubiquitin-like interferon-stimulated gene, promotes hepatitis C virus production in vitro: implications for chronic infection and response to treatment. J Gen Virol 2010; 91: 382-388.
46. Ebihara T, Shingai M, Matsumoto M, Wakita T, Seya T. Hepatitis C virus-infected hepatocytes extrinsically modulate dendritic cell maturation to activate T cells and natural killer cells. Hepatology 2008; 48: 48-58. (Pubitemid 351975530)
47. Decalf J, Fernandes S, Longman R, Ahloulay M, Audat F, Lefrerre F et al. Plasmacytoid dendritic cells initiate a complex chemokine and cytokine network and are a viable drug target in chronic HCV patients. J Exp Med 2007; 204: 2423-2437. (Pubitemid 47529327)
48. Megjugorac NJ, Gallagher GE, Gallagher G. Modulation of human plasmacytoid DC function by IFN-\{lambda\}1 (IL-29). J Leukoc Biol 2009; 86: 1359-1363.
49. Jordan WJ, Eskdale J, Srinivas S, Pekarek V, Kelner D, Rodia M et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes Immun 2007; 8: 254-261. (Pubitemid 46679436)
50. Srinivas S, Dai J, Eskdale J, Gallagher GE, Megjugorac NJ, Gallagher G. Interferon-lambda1 (interleukin-29) preferentially down-regulates interleukin-13 over other T helper type 2 cytokine responses in vitro. Immunology 2008; 125: 492-502.
51. Mennechet FJ, Uzé G. Interferon-lambda-treated dendritic cells specifically induce proliferation of FOXP3-expressing suppressor T cells. Blood 2006; 107: 4417-4423. (Pubitemid 43801368)
52. Morrow MP, Pankhong P, Laddy DJ, Schoenly KA, Yan J, Cisper N et al. Comparative ability of IL-12 and IL-28B to regulate Treg populations and enhance adaptive cellular immunity. Blood 2009; 113: 5868-5877.
53. Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, Storey H et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906. (Pubitemid 46489554)
54. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 2008; 4: e1000017.
55. Jeffers LJ, Cassidy W, Howell CD, Hu S, Reddy KR. Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1. Hepatology 2004; 39: 1702-1708. (Pubitemid 38702672)
56. Muir AJ, Bornstein JD, Killenberg PG. Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites. N Engl J Med 2004; 350: 2265-2271. (Pubitemid 38669209)
57. Missiha S, Heathcote J, Arenovich T, Khan K. Impact of Asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. Am J Gastroenterol 2007; 102: 2181-2188. (Pubitemid 47493845)
58. Liu CH, Liu CJ, Lin CL, Liang CC, Hsu SJ, Yang SS et al. Pegylated interferon-alpha-2a plus ribavirin for treatment-nä?ve Asian patients with hepatitis C virus genotype 1 infection: a multicenter, randomized controlled trial. Clin Infect Dis 2008; 47: 1260-1269.
59. Ueda T, Chung H, Kudo M, Kitai S, Ishikawa E, Yada N et al. Prolonged PEG-IFN and RBV is effective in patients with HCV genotype 1 and high viral load who achieved virological response later than 24 weeks. Intervirology 2010; 53: 55-59.
60. Chen JY, Wang CM, Ma CC, Luo SF, Edberg JC, Kimberly RP et al. Association of a transmembrane polymorphism of Fcgamma receptor IIb (FCGR2B) with systemic lupus erythematosus in Taiwanese patients. Arthritis Rheum 2006; 54: 3908-3917. (Pubitemid 44955894)